PubRank
Search
About
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole (BOLERO-2)
Clinical Trial ID NCT00863655
PubWeight™ 41.74
‹?›
🔗 Visit the ClinicalTrials.gov page for NCT00863655
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
N Engl J Med
2011
13.74
2
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2.
Ann Oncol
2014
2.50
3
Targeted therapies for breast cancer.
J Clin Invest
2011
2.22
4
Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.
J Clin Oncol
2011
2.10
5
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.
Ann Oncol
2014
1.95
6
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.
Adv Ther
2013
1.90
7
Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.
JAMA Oncol
2016
1.83
8
Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.
J Clin Oncol
2015
1.73
9
Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy.
J Hematol Oncol
2009
1.70
10
Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.
Breast Cancer
2013
1.26
11
Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial.
Support Care Cancer
2013
1.05
12
Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions.
Breast Cancer (Auckl)
2013
1.02
13
Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.
Breast Cancer Res Treat
2013
0.99
14
Multidrug-resistant breast cancer: current perspectives.
Breast Cancer (Dove Med Press)
2014
0.99
15
PI3K inhibitors as new cancer therapeutics: implications for clinical trial design.
Onco Targets Ther
2016
0.96
16
Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.
Oncotarget
2014
0.95
17
Models and Mechanisms of Acquired Antihormone Resistance in Breast Cancer: Significant Clinical Progress Despite Limitations.
Horm Mol Biol Clin Investig
2012
0.92
18
Role of mTOR inhibition in preventing resistance and restoring sensitivity to hormone-targeted and HER2-targeted therapies in breast cancer.
Clin Adv Hematol Oncol
2013
0.87
19
The therapeutic potential of mTOR inhibitors in breast cancer.
Br J Clin Pharmacol
2016
0.83
20
Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance.
Clin Breast Cancer
2013
0.83
21
Soy and breast cancer: focus on angiogenesis.
Int J Mol Sci
2015
0.82
22
Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy.
Curr Med Res Opin
2013
0.82
23
Clinical implications of recent studies using mTOR inhibitors to treat advanced hormone receptor-positive breast cancer.
Cancer Manag Res
2014
0.77
24
Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?
Int J Mol Sci
2016
0.75
Next 100